PARP1 and triple-negative breast carcinoma: Iniparib was initially developed as a poly adenosine diphosphate ribose polymerase 1 (PARP1) inhibitor; however, current knowledge indicates that its activity is not linked to PARP inhibition as originally thought.[1,2] The integration of iniparib into cancer treatment protocols was originally supported by encouraging results from initial human clinical trials, specifically in the treatment of metastatic triple-negative breast cancer (TNBC).[3] However, a later stage, phase III study did not meet its primary endpoints of demonstrating an improvement in progression-free and overall survival.